The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia

被引:71
|
作者
Zalewska-Szewczyk, Beata
Andrzejewski, Witalij
Mlynarski, Wojciech
Jedrychowska-Danska, Krystyna
Witas, Henryk
Bodalski, Jerzy
机构
[1] Med Univ Lodz, Oncohematol Unit, Dept Pediat, PL-91738 Lodz, Poland
[2] Med Univ Lodz, Dept Biol Mol, Lodz, Poland
关键词
L-asparaginase; antibodies; allergy; acute lymphoblastic leukemia; children;
D O I
10.1080/10428190701292049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The primary aim of the study was to evaluate the importance of anti-asparaginase antibodies for L-asparaginase activity in children with standard and medium risk acute lymphoblastic leukemia ( ALL). Forty-seven children with newly diagnosed ALL were included into the prospective study. Enzyme activity and the presence of anti-asparaginase antibodies ( IgG and IgM class) were determined. Anti-asparaginase antibodies were identified in 13/47 ( IgM class) and 10/ 47 ( IgG class) patients in the induction and in 19/47 ( IgM class) and 20/47 ( IgG class) patients in the reinduction phase of treatment. The enzyme activity was lower in patients that were positive for anti-asparaginase antibodies, especially in reinduction phase ( median 37 ( 20-180) vs 355 ( 141-499), p = 0.001). An association between anti-asparaginase antibodies and the allergic reaction to the drug was found. Besides, the children who developed anti-asparaginase antibodies in the induction phase of treatment showed lower event-free survival as well as overall survival in comparison with children without antibodies. Since our study was carried out in a small number of patients, this observation is only speculative and needs to be confirmed by a further study on a larger sample size, with multivariable analysis. However, our data suggest that L-asparaginase activity together with anti-asparaginase antibodies measurements may become useful for effective therapy of ALL.
引用
收藏
页码:931 / 936
页数:6
相关论文
共 50 条
  • [21] VARIATION BY RACE IN PRESENTING CLINICAL AND BIOLOGIC FEATURES OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - IMPLICATIONS FOR TREATMENT OUTCOME
    KALWINSKY, DK
    RIVERA, G
    DAHL, GV
    ROBERSON, P
    GEORGE, S
    MURPHY, SB
    SIMONE, JV
    LEUKEMIA RESEARCH, 1985, 9 (06) : 817 - 823
  • [22] The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia
    Wojtuszkiewicz, Anna
    Assaraf, Yehuda G.
    Hoekstra, Mirthe
    Jansen, Gerrit
    Peters, Godefridus J.
    Sonneveld, Edwin
    Kaspers, Gertjan L.
    Cloos, Jacqueline
    CANCER RESEARCH, 2015, 75
  • [23] Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia
    L J Ashton
    A J Gifford
    E Kwan
    A Lingwood
    D T T Lau
    G M Marshall
    M Haber
    M D Norris
    Leukemia, 2009, 23 : 1348 - 1351
  • [24] Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia
    Ashton, L. J.
    Gifford, A. J.
    Kwan, E.
    Lingwood, A.
    Lau, D. T. T.
    Marshall, G. M.
    Haber, M.
    Norris, M. D.
    LEUKEMIA, 2009, 23 (07) : 1348 - 1351
  • [25] CLINICAL-SIGNIFICANCE OF CYTOSTASIS ACTIVITY OF MONONUCLEAR-CELLS IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    KAWAI, H
    HIRABAYASHI, S
    MIYAGAWA, Y
    KOMIYAMA, A
    AKABANE, T
    CANCER, 1983, 52 (07) : 1215 - 1219
  • [26] Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia
    Karai, Bettina
    Gyurina, Katalin
    Ujfalusi, Aniko
    Sedek, Lukasz
    Barna, Gabor
    Jakso, Pal
    Svec, Peter
    Szantho, Eszter
    Nagy, Attila Csaba
    Mueller, Judit
    Simon, Reka
    Vojczek, Agnes
    Szegedi, Istvan
    Tiszlavicz, Lilla Gyorgyi
    Kowalczyk, Jerzy R.
    Kolenova, Alexandra
    Kovacs, Gabor T.
    Szczepanski, Tomasz
    Dworzak, Michael
    Schumich, Angela
    Attarbaschi, Andishe
    Nebral, Karin
    Haas, Oskar A.
    Kappelmayer, Janos
    Hevessy, Zsuzsanna
    Kiss, Csongor
    CANCERS, 2020, 12 (08) : 1 - 17
  • [27] Overexpression of the AEP gene in childhood acute lymphoblastic leukemia with dup(21q) may contribute to therapeutic outcome.
    Van Delft, Frederik W.
    Yiannikouris, Olga
    Salhimi, Salizawati
    Moss, Catherine
    Jones, Louise K.
    Senderovich, Shai
    Patel, Naina
    Alexander, Seema
    Krishnan, Shekhar
    Strefford, Jon C.
    Raghavan, Manoj
    Young, Bryan D.
    Harrison, Christine J.
    Bonnet, Dominique
    Watts, Colin
    Hart, Ian
    Saha, Vaskar
    CANCER RESEARCH, 2006, 66 (08)
  • [28] Clinical presentation, hematologic features and treatment outcome of childhood acute lymphoblastic leukemia: A review of 73 cases in Hong Kong
    Ma, SK
    Chan, GCF
    Ha, SY
    Chiu, DCK
    Lau, YL
    Chan, LC
    HEMATOLOGICAL ONCOLOGY, 1997, 15 (03) : 141 - 149
  • [29] RELATION OF CELLULAR-DRUG RESISTANCE TO LONG-TERM CLINICAL OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    PIETERS, R
    HUISMANS, DR
    LOONEN, AH
    HAHLEN, K
    VANDERDOESVANDENBERG, A
    VANWERING, ER
    VEERMAN, AJP
    LANCET, 1991, 338 (8764): : 399 - 403
  • [30] Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials
    M Dördelmann
    M Schrappe
    A Reiter
    M Zimmermann
    N Graf
    G Schott
    F Lampert
    J Harbott
    C Niemeyer
    J Ritter
    W Dörffel
    G Neßler
    J Kühl
    H Riehm
    Leukemia, 1998, 12 : 645 - 651